Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662097 · ClinicalTrials.gov registry record · Phase 2
A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery
A Phase 2 study of Surgery and Nerve Injury, sponsored by Alume Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06662097: Recruiting Phase 2 study of Surgery and Nerve Injury, sponsored by Alume Biosciences.
NCT06662097 is a Phase 2 study of Surgery and Nerve Injury that is actively recruiting participants, run by Alume Biosciences. The registered enrollment target is 64 participants, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06662097, a Phase 2 study of Surgery and Nerve Injury, is actively recruiting participants, sponsored by Alume Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery
Primary Outcome
To assess the feasibility of the Fluorescence System in each of the identified Minimally Invasive Surgery settings.
Conditions Studied
Interventions
- DRUG Bevonescein
Study Locations (1)
California
- University of California San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2025-09 |
| Phase | Phase 2 |
What NCT06662097 shows while recruiting
NCT06662097 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Surgery appearing as the primary indexed condition, and to 1 intervention - of which Bevonescein is the first listed.
NCT06662097 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06662097 about?
NCT06662097 is a clinical study titled "A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery". Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery
What is the current status of trial NCT06662097?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2024-10-16. Estimated completion is 2025-09.
What conditions does trial NCT06662097 study?
This clinical trial studies the following conditions: Surgery, Nerve Injury, Imaging.
What interventions are being tested in trial NCT06662097?
The interventions under investigation include: Bevonescein (DRUG).
Who is sponsoring clinical trial NCT06662097?
This trial is sponsored by Alume Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06662097 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06662097's enrollment target sits among peer trials
64 79th of 120 higher than 41 of 120 other Surgery trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgery trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery
RECRUITING · Phase 2
-
Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription
COMPLETED · Phase 2
-
Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
COMPLETED · Phase 2
-
Terumo Aortic Global Endovascular Registry
RECRUITING
-
A Study of the Use of 3D Technology to Guide Head and Neck Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI